Business Standard

Zydus receives market authorisation for Morphine Sulfate ER Tablets

Image

Capital Market

To be manufactured at Nesher Pharmaceuticals, USA

Cadila Healthcare announced that the Zydus group has received the market authorisation from the USFDA to market Morphine Sulfate ER Tablets. The product used in the treatment of chronic pain or cancer related pain will be manufactured at Nesher Pharmaceuticals, USA.

Powered by Capital Market - Live News

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 01 2015 | 3:02 PM IST

Explore News